Relovair fluticasone furoate/vilanterol: Pivotal trial data

Top-line data from a 4-week, Phase III lung function profile trial in 54 patients showed that 50/25 µg, 100/25 µg, and 200/25 µg Relovair fluticasone furoate/vilanterol significantly increased weighted mean FEV1 vs. placebo. Last year, the companies reported data from a pair of 6-month, double-blind Phase III trials showing that Relovair met 5 of the 6 co-primary endpoints (see BioCentury, June 6, 2011). ...